Search

Your search keyword '"Chuang, Chi-Mu"' showing total 135 results
Start Over Author "Chuang, Chi-Mu" Publication Year Range Last 10 years
135 results on '"Chuang, Chi-Mu"'

8. Women with endometriosis have higher comorbidities: Analysis of domestic data in Taiwan

Author

Chang, Yen-Hou, Chang, Yi, Chao, Kuan-Chong, Chen, Yi-Jen, Chuang, Chi-Mu, Huang, Chen-Yu, Jiang, Ling-Yu, Li, Hsin-Yang, Liu, Chia-Hao, Sun, Pi-Lin, Wen, Kuo-Chang, Wu, Hua-Hsi, Yu, Hann-Chin, Ju, Fong-Yuan, Tsai, Chih-Ping, Chang, Wen-Hsun, Hsu, Yen-Mei, Huang, Shu-Yun, Lee, Na-Rong, Chen, Chih-Yao, Chang, Ting-Chen, Chang, Wen-Chun, Chen, Chii-Hou, Chen, Ruey-Jian, Chow, Song-Nan, Lien, Yih-Ron, Sheu, Bor-Ching, Torng, Pao-Ling, Yen, Men-Luh, Lee, Wen-Ling, Wang, Kuan-Chin, Chang, Chih-Long, Chen, Chih-Ping, Chen, Jen-Ruei, Chen, Tze-Chien, Huang, Jian-Pei, Huang, Ming-Chao, Wang, Yeou-Lih, Chang, Cheng-Chang, Liu, Jah-Yao, Su, Her-Young, Wang, Yu-Chi, Yu, Mu-Hsien, Chu, Ching-Chuang, Huang, Lee-Wen, Seow, Kok-Min, Lai, Tsung-Hsuan, Lee, Fa-Kung, Chen, Ching-Hui, Liu, Wei-Min, Chiou, Jyh-Shin, Huang, Ben-Shian, Lu, Yen-Feng, Hsiao, Sheng-Mou, Sun, Hsu-Dong, Wu, Wen-Yih, Chen, Kuo-Hu, Hung, Jeng-Hsiu, Lai, Hung-Cheng, Yuan, Chiou-Chung, Hsieh, Ching-Hung, Wang, Chin-Jung, Chan, Chia-Hao, Chang, Shing-Jyh, Shih, Chuan-Chi, Hung, Man-Jung, Hsu, Shih-Tien, Ke, Yu-Min, Lu, Chien-Hsing, Sun, Lou, Chang, Wei-Chun, Hung, Yao-Ching, Lin, Wu-Chou, Wang, Po-Hui, Chen, Tze-Ho, Li, Yiu-Tai, Wu, Meng-Hsing, Huang, Kuo-Feng, Chuang, Fei-Chi, Fu, Hung-Chun, Kung, Fu-Tsai, Huang, Kuan-Hui, Chen, San-Nung, Chiang, An-Jen, Li, Ju-Yueh, Lin, Li-Te, Tsai, Hsiao-Wen, Tsui, Kuan-Hao, Teng, Sen-Wen, Horng, Huann-Cheng, Ho, Chi-Hong, Yen, Ming-Shyen, Chao, Hsiang-Tai, and Wang, Peng-Hui

Published
2016
Full Text
View/download PDF

9. Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Author

Chang, Yen-Hou, Chang, Yi, Chao, Hsiang-Tai, Chao, Kuan-Chong, Chuang, Chi-Mu, Ho, Chi-Hong, Horng, Huann-Cheng, Huang, Chen-Yu, Jiang, Ling-Yu, Liu, Chia-Hao, Li, Hsin-Yang, Sun, Pi-Lin, Wu, Hua-Hsi, Ju, Fong-Yuan, Tsai, Chih-Ping, Chang, Wen-Hsun, Hsu, Yen-Mei, Huang, Shu-Yun, Lee, Na-Rong, Chen, Chih-Yao, Chang, Wen-Chun, Chen, Chii-Hou, Chen, Ruey-Jian, Chow, Song-Nan, Lien, Yih-Ron, Sheu, Bor-Ching, Torng, Pao-Ling, Wei, Lin-Hung, Yen, Men-Luh, Lee, Wen-Ling, Wang, Kuan-Chin, Chang, Chih-Long, Chen, Chih-Ping, Chen, Tze-Chien, Huang, Jian-Pei, Huang, Ming-Chao, Wang, Yeou-Lih, Chang, Cheng-Chang, Liu, Jah-Yao, Su, Her-Young, Wang, Yu-Chi, Yu, Mu-Hsien, Chu, Ching-Chuang, Huang, Lee-Wen, Seow, Kok-Min, Lai, Tsung-Hsuan, Lee, Fa-Kung, Chen, Ching-Hui, Liu, Wei-Min, Chiou, Jyh-Shin, Huang, Ben-Shian, Lu, Yen-Feng, Hsiao, Sheng-Mou, Sun, Hsu-Dong, Wu, Wen-Yih, Teng, Sen-Wen, Chen, Kuo-Hu, Hung, Jeng-Hsiu, Lai, Hung-Cheng, Yuan, Chiou-Chung, Hsieh, Ching-Hung, Wang, Chin-Jung, Chan, Chia-Hao, Chang, Shing-Jyh, Shih, Chuan-Chi, Hung, Man-Jung, Hsu, Shih-Tien, Ke, Yu-Min, Lu, Chien-Hsing, Sun, Lou, Chang, Wei-Chun, Hung, Yao-Ching, Lin, Wu-Chou, Wang, Po-Hui, Chen, Tze-Ho, Wu, Meng-Hsing, Li, Yiu-Tai, Huang, Kuo-Feng, Chuang, Fei-Chi, Fu, Hung-Chun, Kung, Fu-Tsai, Huang, Kuan-Hui, Chen, San-Nung, Chiang, An-Jen, Li, Ju-Yueh, Liou, Wen-Shiung, Lin, Li-Te, Tsai, Hsiao-Wen, Tsui, Kuan-Hao, Yen, Ming-Shyen, Chen, Jen-Ruei, Wang, Peng-Hui, Wen, Kuo-Chang, Chen, Yi-Jen, and Ng, Heung-Tat

Published
2016
Full Text
View/download PDF

11. Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review

Author

Chang, Yen-Hou, Chang, Yi, Chao, Hsiang-Tai, Chao, Kuan-Chong, Chuang, Chi-Mu, Ho, Chi-Hong, Huang, Chen-Yu, Hung, Zhi-Chen, Jiang, Ling-Yu, Lau, Hei-Yu, Li, Hsin-Yang, Lin, Chi-Yao, Liu, Chia-Hao, Sun, Pi-Lin, Twu, Nae-Fang, Wu, Hua-Hsi, Yu, Hann-Chin, Ju, Fong-Yuan, Tsai, Chih-Ping, Chang, Wen-Hsun, Hsu, Yen-Mei, Lee, Na-Rong, Chen, Chih-Yao, Chang, Ting-Chen, Chang, Wen-Chun, Chen, Chii-Hou, Chen, Ruey-Jian, Chow, Song-Nan, Lien, Yih-Ron, Sheu, Bor-Ching, Torng, Pao-Ling, Yen, Men-Luh, Lee, Wen-Ling, Wang, Kuan-Chin, Chang, Chih-Long, Chen, Chih-Ping, Chen, Jen-Ruei, Chen, Tze-Chien, Huang, Jian-Pei, Huang, Ming-Chao, Wang, Yeou-Lih, Chang, Cheng-Chang, Liu, Jah-Yao, Su, Her-Young, Wang, Yu-Chi, Yu, Mu-Hsien, Huang, Lee-Wen, Seow, Kok-Min, Lai, Tsung-Hsuan, Lee, Fa-Kung, Chen, Ching-Hui, Huang, Ben-Shian, Hsiao, Sheng-Mou, Sun, Hsu-Dong, Wu, Wen-Yih, Teng, Sen-Wen, Chen, Kuo-Hu, Hung, Jeng-Hsiu, Lai, Hung-Cheng, Yuan, Chiou-Chung, Hsieh, Ching-Hung, Wang, Chin-Jung, Chang, Shing-Jyh, Hung, Man-Jung, Hsu, Shih-Tien, Ke, Yu-Min, Lu, Chien-Hsing, Sun, Lou, Chang, Wei-Chun, Hung, Yao-Ching, Lin, Wu-Chou, Wang, Po-Hui, Chen, Tze-Ho, Li, Yiu-Tai, Wu, Meng-Hsing, Huang, Kuo-Feng, Fu, Hung-Chun, Chen, San-Nung, Chiang, An-Jen, Li, Ju-Yueh, Lin, Li-Te, Tsai, Hsiao-Wen, Tsui, Kuan-Hao, Horng, Huann-Cheng, Wen, Kuo-Chang, Wang, Peng-Hui, Chen, Yi-Jen, Yen, Ming-Shyen, and Ng, Heung-Tat

Published
2016
Full Text
View/download PDF

12. Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review

Author

Chang, Yen-Hou, Chang, Yi, Chao, Hsiang-Tai, Chao, Kuan-Chong, Chuang, Chi-Mu, Ho, Chi-Hong, Huang, Chen-Yu, Hung, Zhi-Chen, Jiang, Ling-Yu, Lau, Hei-Yu, Li, Hsin-Yang, Lin, Chi-Yao, Liu, Chia-Hao, Sun, Pi-Lin, Twu, Nae-Fang, Wu, Hua-Hsi, Yu, Hann-Chin, Ju, Fong-Yuan, Tsai, Chih-Ping, Chang, Wen-Hsun, Hsu, Yen-Mei, Lee, Na-Rong, Chen, Chih-Yao, Chang, Ting-Chen, Chang, Wen-Chun, Chen, Chii-Hou, Chen, Ruey-Jian, Chow, Song-Nan, Lien, Yih-Ron, Sheu, Bor-Ching, Torng, Pao-Ling, Yen, Men-Luh, Lee, Wen-Ling, Wang, Kuan-Chin, Chang, Chih-Long, Chen, Chih-Ping, Chen, Jen-Ruei, Chen, Tze-Chien, Huang, Jian-Pei, Huang, Ming-Chao, Wang, Yeou-Lih, Chang, Cheng-Chang, Liu, Jah-Yao, Su, Her-Young, Wang, Yu-Chi, Yu, Mu-Hsien, Huang, Lee-Wen, Seow, Kok-Min, Lai, Tsung-Hsuan, Lee, Fa-Kung, Chen, Ching-Hui, Huang, Ben-Shian, Hsiao, Sheng-Mou, Sun, Hsu-Dong, Wu, Wen-Yih, Teng, Sen-Wen, Chen, Kuo-Hu, Hung, Jeng-Hsiu, Lai, Hung-Cheng, Yuan, Chiou-Chung, Hsieh, Ching-Hung, Wang, Chin-Jung, Chang, Shing-Jyh, Hung, Man-Jung, Hsu, Shih-Tien, Ke, Yu-Min, Lu, Chien-Hsing, Sun, Lou, Chang, Wei-Chun, Hung, Yao-Ching, Lin, Wu-Chou, Wang, Po-Hui, Chen, Tze-Ho, Li, Yiu-Tai, Wu, Meng-Hsing, Huang, Kuo-Feng, Fu, Hung-Chun, Chen, San-Nung, Chiang, An-Jen, Li, Ju-Yueh, Lin, Li-Te, Tsai, Hsiao-Wen, Tsui, Kuan-Hao, Wen, Kuo-Chang, Horng, Huann-Cheng, Wang, Peng-Hui, Chen, Yi-Jen, Yen, Ming-Shyen, and Ng, Heung-Tat

Published
2016
Full Text
View/download PDF

14. Comparison of single-incision mini-slings (Ajust) and standard transobturator midurethral slings (Align) in the management of female stress urinary incontinence: A 1-year follow-up

Author

Chuang, Chi-Mu, Chang, Yen-Hou, Wu, Hua-Hsi, Lau, Hei-Yu, Tseng, Jen-Yu, Tsai, Hsiao-Wen, Twu, Nae-Fong, Chao, Hsiang-Tai, Chang, Chia-Pei, Chang, Wen-Hsun, Hsu, Yen-Mei, Chen, Yi-Jen, Wen, Kuo-Chang, Chao, Kuan-Chong, Yen, Ming-Shyen, Horng, Huann-Cheng, and Wang, Peng-Hui

Published
2015
Full Text
View/download PDF

20. A Cationic Amphipathic Tilapia Piscidin 4 Peptide-Based Antimicrobial Formulation Promotes Eradication of Bacterial Vaginosis-Associated Bacterial Biofilms

Author

Lin, Wen-Chun, Chen, Yun-Ru, Chuang, Chi-Mu, and Chen, Jyh-Yih

Subjects
Microbiology (medical), Microbiology
Abstract

Bacterial vaginosis (BV) is prevalent among women of reproductive age and has a high rate of recurrence, which can be largely attributed to ineffective BV biofilm eradication by current first-line antibiotics. In this study, we report that the Nile tilapia piscidin 4 (TP4) exhibits broad-spectrum antimicrobial and antibiofilm activity against BV-associated bacteria, but not beneficial lactobacilli. In addition, BV-associated Gardnerella vaginalis remains susceptible to TP4 even after continual exposure to the peptide for up to 22 passages. Gardnerella vaginalis and Streptococcus anginosus are both biofilm-forming BV-associated bacteria, and we found that combining TP4 peptide and disodium EDTA with the biofilm-disrupting agent, chitosan, can eradicate biofilms formed by single or mixed G. vaginalis and S. anginosus. In addition, long-term storage of TP4 peptide in chitosan did not diminish its bactericidal activity toward G. vaginalis. Preformulation studies were performed using High performance liquid chromatography (HPLC) and Circular Dichroism (CD). The long-term stability of TP4 peptide was assessed under various conditions, such as different temperatures and ionic strengths, and in the presence of H2O2 and lactic acid. When exposed to sodium dodecyl sulfate (SDS), TP4 maintained its secondary structure at various temperatures, salt and disodium EDTA concentrations. Furthermore, the TP4 microbicide formulation significantly reduced the colonization density of BV-associated bacteria in mice infected with single or mixed bacteria (G. vaginalis and S. anginosus). The TP4 microbicide formulation showed biocompatibility with beneficial human vaginal lactobacilli and female reproductive tissues in C57BL/6 mice. These results suggest that the TP4 microbicide formulation could be a promising topical microbicide agent for BV treatment.

Published
2022

25. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers

Author

Shen, Yao-An, primary, Hong, Jiaxin, additional, Asaka, Ryoichi, additional, Asaka, Shiho, additional, Hsu, Fang-Chi, additional, Suryo Rahmanto, Yohan, additional, Jung, Jin-Gyoung, additional, Chen, Yu-Wei, additional, Yen, Ting-Tai, additional, Tomaszewski, Alicja, additional, Zhang, Cissy, additional, Attarwala, Nabeel, additional, DeMarzo, Angelo M., additional, Davidson, Ben, additional, Chuang, Chi-Mu, additional, Chen, Xi, additional, Gaillard, Stephanie, additional, Le, Anne, additional, Shih, Ie-Ming, additional, and Wang, Tian-Li, additional

Published
2020
Full Text
View/download PDF

28. Increased Association Between Endometriosis and Endometrial Cancer

Author

Yu, Hann-Chin, Lin, Chun-Yi, Chang, Wei-Chiao, Shen, Biing-Jiun, Chang, Wei-Pin, and Chuang, Chi-Mu

Subjects
Adult, Incidence, Endometriosis, Taiwan, Middle Aged, Endometrial Neoplasms, Uterine Cancer, Population-based cohort study, Endometrial cancer, Risk Factors, Case-Control Studies, Humans, Female, Longitudinal Studies, Age of Onset, Proportional Hazards Models, Retrospective Studies
Abstract

Objective Association between endometriosis and ovarian cancer has been well established. Nonetheless, endometriosis may also be associated with endometrial cancer because of shared etiological mechanisms of both estrogen stimulation and chronic inflammation; however, the association between these 2 disorders has rarely been investigated. Methods The National Health Insurance Research Databases in Taiwan were retrieved and analyzed. The case cohort consisted of patients with a diagnosis of endometriosis between January 1997 and December 2000 (N = 15,488). For the construction of control cohort, 8 age- and sex-matched control patients for every patient in the case cohort were selected using a random sampling method (n = 123,904). All subjects were tracked for 10 years from the date of entry to identify whether they had developed endometrial cancer. The Cox proportional hazards regression model was used to evaluate 10-year event occurrence of endometrial cancer. Results During the 10-year follow-up period, 392 participants developed endometrial cancer, with 104 (0.7%) distributed in the case cohort and 288 (0.2%) in the control cohort. Multivariable Cox regression modeling demonstrates a higher risk for developing endometrial cancer in the case cohort than in the control cohort (adjusted hazard ratio [aHR], 2.83; 95% confidence interval [CI], 1.495.35; P < 0.01). Age at diagnosis of endometriosis shows a moderator effect: when 40 years or younger, the risk for developing endometrial cancer was comparable between the case cohort and the control cohort (aHR, 1.42; 95% CI, 0.55–3.70; P = 0.226), whereas when older than 40 years, the risk for developing endometrial cancer was higher in the former group than in the latter group (aHR, 7.08; 95% CI, 2.33–21.55; P = 0.007). Conclusions Patients diagnosed with endometriosis may harbor an increased risk for developing endometrial cancer in their later life. Closer monitoring is advised for this patient population.

Published
2015

32. The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels

Author

Sung, Pi-Lin, primary, Wen, Kuo-Chang, additional, Chen, Yi-Jen, additional, Chao, Ta-Chung, additional, Tsai, Yi-Fang, additional, Tseng, Ling-Ming, additional, Qiu, Jian-Tai Timothy, additional, Chao, Kuan-Chong, additional, Wu, Hua-Hsi, additional, Chuang, Chi-Mu, additional, Wang, Peng-Hui, additional, and Huang, Chi-Ying F., additional

Published
2017
Full Text
View/download PDF

35. Women with endometriosis have higher comorbidities: Analysis of domestic data in Taiwan

Author

Teng, Sen-Wen, primary, Horng, Huann-Cheng, additional, Ho, Chi-Hong, additional, Yen, Ming-Shyen, additional, Chao, Hsiang-Tai, additional, Wang, Peng-Hui, additional, Chang, Yen-Hou, additional, Chang, Yi, additional, Chao, Kuan-Chong, additional, Chen, Yi-Jen, additional, Chuang, Chi-Mu, additional, Huang, Chen-Yu, additional, Jiang, Ling-Yu, additional, Li, Hsin-Yang, additional, Liu, Chia-Hao, additional, Sun, Pi-Lin, additional, Wen, Kuo-Chang, additional, Wu, Hua-Hsi, additional, Yu, Hann-Chin, additional, Ju, Fong-Yuan, additional, Tsai, Chih-Ping, additional, Chang, Wen-Hsun, additional, Hsu, Yen-Mei, additional, Huang, Shu-Yun, additional, Lee, Na-Rong, additional, Chen, Chih-Yao, additional, Chang, Ting-Chen, additional, Chang, Wen-Chun, additional, Chen, Chii-Hou, additional, Chen, Ruey-Jian, additional, Chow, Song-Nan, additional, Lien, Yih-Ron, additional, Sheu, Bor-Ching, additional, Torng, Pao-Ling, additional, Yen, Men-Luh, additional, Lee, Wen-Ling, additional, Wang, Kuan-Chin, additional, Chang, Chih-Long, additional, Chen, Chih-Ping, additional, Chen, Jen-Ruei, additional, Chen, Tze-Chien, additional, Huang, Jian-Pei, additional, Huang, Ming-Chao, additional, Wang, Yeou-Lih, additional, Chang, Cheng-Chang, additional, Liu, Jah-Yao, additional, Su, Her-Young, additional, Wang, Yu-Chi, additional, Yu, Mu-Hsien, additional, Chu, Ching-Chuang, additional, Huang, Lee-Wen, additional, Seow, Kok-Min, additional, Lai, Tsung-Hsuan, additional, Lee, Fa-Kung, additional, Chen, Ching-Hui, additional, Liu, Wei-Min, additional, Chiou, Jyh-Shin, additional, Huang, Ben-Shian, additional, Lu, Yen-Feng, additional, Hsiao, Sheng-Mou, additional, Sun, Hsu-Dong, additional, Wu, Wen-Yih, additional, Chen, Kuo-Hu, additional, Hung, Jeng-Hsiu, additional, Lai, Hung-Cheng, additional, Yuan, Chiou-Chung, additional, Hsieh, Ching-Hung, additional, Wang, Chin-Jung, additional, Chan, Chia-Hao, additional, Chang, Shing-Jyh, additional, Shih, Chuan-Chi, additional, Hung, Man-Jung, additional, Hsu, Shih-Tien, additional, Ke, Yu-Min, additional, Lu, Chien-Hsing, additional, Sun, Lou, additional, Chang, Wei-Chun, additional, Hung, Yao-Ching, additional, Lin, Wu-Chou, additional, Wang, Po-Hui, additional, Chen, Tze-Ho, additional, Li, Yiu-Tai, additional, Wu, Meng-Hsing, additional, Huang, Kuo-Feng, additional, Chuang, Fei-Chi, additional, Fu, Hung-Chun, additional, Kung, Fu-Tsai, additional, Huang, Kuan-Hui, additional, Chen, San-Nung, additional, Chiang, An-Jen, additional, Li, Ju-Yueh, additional, Lin, Li-Te, additional, Tsai, Hsiao-Wen, additional, and Tsui, Kuan-Hao, additional

Published
2016
Full Text
View/download PDF

36. Uterine sarcoma part III—Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review

Author

Yen, Ming-Shyen, primary, Chen, Jen-Ruei, additional, Wang, Peng-Hui, additional, Wen, Kuo-Chang, additional, Chen, Yi-Jen, additional, Ng, Heung-Tat, additional, Chang, Yen-Hou, additional, Chang, Yi, additional, Chao, Hsiang-Tai, additional, Chao, Kuan-Chong, additional, Chuang, Chi-Mu, additional, Ho, Chi-Hong, additional, Horng, Huann-Cheng, additional, Huang, Chen-Yu, additional, Jiang, Ling-Yu, additional, Liu, Chia-Hao, additional, Li, Hsin-Yang, additional, Sun, Pi-Lin, additional, Wu, Hua-Hsi, additional, Ju, Fong-Yuan, additional, Tsai, Chih-Ping, additional, Chang, Wen-Hsun, additional, Hsu, Yen-Mei, additional, Huang, Shu-Yun, additional, Lee, Na-Rong, additional, Chen, Chih-Yao, additional, Chang, Wen-Chun, additional, Chen, Chii-Hou, additional, Chen, Ruey-Jian, additional, Chow, Song-Nan, additional, Lien, Yih-Ron, additional, Sheu, Bor-Ching, additional, Torng, Pao-Ling, additional, Wei, Lin-Hung, additional, Yen, Men-Luh, additional, Lee, Wen-Ling, additional, Wang, Kuan-Chin, additional, Chang, Chih-Long, additional, Chen, Chih-Ping, additional, Chen, Tze-Chien, additional, Huang, Jian-Pei, additional, Huang, Ming-Chao, additional, Wang, Yeou-Lih, additional, Chang, Cheng-Chang, additional, Liu, Jah-Yao, additional, Su, Her-Young, additional, Wang, Yu-Chi, additional, Yu, Mu-Hsien, additional, Chu, Ching-Chuang, additional, Huang, Lee-Wen, additional, Seow, Kok-Min, additional, Lai, Tsung-Hsuan, additional, Lee, Fa-Kung, additional, Chen, Ching-Hui, additional, Liu, Wei-Min, additional, Chiou, Jyh-Shin, additional, Huang, Ben-Shian, additional, Lu, Yen-Feng, additional, Hsiao, Sheng-Mou, additional, Sun, Hsu-Dong, additional, Wu, Wen-Yih, additional, Teng, Sen-Wen, additional, Chen, Kuo-Hu, additional, Hung, Jeng-Hsiu, additional, Lai, Hung-Cheng, additional, Yuan, Chiou-Chung, additional, Hsieh, Ching-Hung, additional, Wang, Chin-Jung, additional, Chan, Chia-Hao, additional, Chang, Shing-Jyh, additional, Shih, Chuan-Chi, additional, Hung, Man-Jung, additional, Hsu, Shih-Tien, additional, Ke, Yu-Min, additional, Lu, Chien-Hsing, additional, Sun, Lou, additional, Chang, Wei-Chun, additional, Hung, Yao-Ching, additional, Lin, Wu-Chou, additional, Wang, Po-Hui, additional, Chen, Tze-Ho, additional, Wu, Meng-Hsing, additional, Li, Yiu-Tai, additional, Huang, Kuo-Feng, additional, Chuang, Fei-Chi, additional, Fu, Hung-Chun, additional, Kung, Fu-Tsai, additional, Huang, Kuan-Hui, additional, Chen, San-Nung, additional, Chiang, An-Jen, additional, Li, Ju-Yueh, additional, Liou, Wen-Shiung, additional, Lin, Li-Te, additional, Tsai, Hsiao-Wen, additional, and Tsui, Kuan-Hao, additional

Published
2016
Full Text
View/download PDF

38. Uterine sarcoma Part I—Uterine leiomyosarcoma: The Topic Advisory Group systematic review

Author

Wen, Kuo-Chang, primary, Horng, Huann-Cheng, additional, Wang, Peng-Hui, additional, Chen, Yi-Jen, additional, Yen, Ming-Shyen, additional, Ng, Heung-Tat, additional, Chang, Yen-Hou, additional, Chang, Yi, additional, Chao, Hsiang-Tai, additional, Chao, Kuan-Chong, additional, Chuang, Chi-Mu, additional, Ho, Chi-Hong, additional, Huang, Chen-Yu, additional, Hung, Zhi-Chen, additional, Jiang, Ling-Yu, additional, Lau, Hei-Yu, additional, Li, Hsin-Yang, additional, Lin, Chi-Yao, additional, Liu, Chia-Hao, additional, Sun, Pi-Lin, additional, Twu, Nae-Fang, additional, Wu, Hua-Hsi, additional, Yu, Hann-Chin, additional, Ju, Fong-Yuan, additional, Tsai, Chih-Ping, additional, Chang, Wen-Hsun, additional, Hsu, Yen-Mei, additional, Lee, Na-Rong, additional, Chen, Chih-Yao, additional, Chang, Ting-Chen, additional, Chang, Wen-Chun, additional, Chen, Chii-Hou, additional, Chen, Ruey-Jian, additional, Chow, Song-Nan, additional, Lien, Yih-Ron, additional, Sheu, Bor-Ching, additional, Torng, Pao-Ling, additional, Yen, Men-Luh, additional, Lee, Wen-Ling, additional, Wang, Kuan-Chin, additional, Chang, Chih-Long, additional, Chen, Chih-Ping, additional, Chen, Jen-Ruei, additional, Chen, Tze-Chien, additional, Huang, Jian-Pei, additional, Huang, Ming-Chao, additional, Wang, Yeou-Lih, additional, Chang, Cheng-Chang, additional, Liu, Jah-Yao, additional, Su, Her-Young, additional, Wang, Yu-Chi, additional, Yu, Mu-Hsien, additional, Huang, Lee-Wen, additional, Seow, Kok-Min, additional, Lai, Tsung-Hsuan, additional, Lee, Fa-Kung, additional, Chen, Ching-Hui, additional, Huang, Ben-Shian, additional, Hsiao, Sheng-Mou, additional, Sun, Hsu-Dong, additional, Wu, Wen-Yih, additional, Teng, Sen-Wen, additional, Chen, Kuo-Hu, additional, Hung, Jeng-Hsiu, additional, Lai, Hung-Cheng, additional, Yuan, Chiou-Chung, additional, Hsieh, Ching-Hung, additional, Wang, Chin-Jung, additional, Chang, Shing-Jyh, additional, Hung, Man-Jung, additional, Hsu, Shih-Tien, additional, Ke, Yu-Min, additional, Lu, Chien-Hsing, additional, Sun, Lou, additional, Chang, Wei-Chun, additional, Hung, Yao-Ching, additional, Lin, Wu-Chou, additional, Wang, Po-Hui, additional, Chen, Tze-Ho, additional, Li, Yiu-Tai, additional, Wu, Meng-Hsing, additional, Huang, Kuo-Feng, additional, Fu, Hung-Chun, additional, Chen, San-Nung, additional, Chiang, An-Jen, additional, Li, Ju-Yueh, additional, Lin, Li-Te, additional, Tsai, Hsiao-Wen, additional, and Tsui, Kuan-Hao, additional

Published
2016
Full Text
View/download PDF

39. Uterine sarcoma Part II—Uterine endometrial stromal sarcoma: The TAG systematic review

Author

Horng, Huann-Cheng, primary, Wen, Kuo-Chang, additional, Wang, Peng-Hui, additional, Chen, Yi-Jen, additional, Yen, Ming-Shyen, additional, Ng, Heung-Tat, additional, Chang, Yen-Hou, additional, Chang, Yi, additional, Chao, Hsiang-Tai, additional, Chao, Kuan-Chong, additional, Chuang, Chi-Mu, additional, Ho, Chi-Hong, additional, Huang, Chen-Yu, additional, Hung, Zhi-Chen, additional, Jiang, Ling-Yu, additional, Lau, Hei-Yu, additional, Li, Hsin-Yang, additional, Lin, Chi-Yao, additional, Liu, Chia-Hao, additional, Sun, Pi-Lin, additional, Twu, Nae-Fang, additional, Wu, Hua-Hsi, additional, Yu, Hann-Chin, additional, Ju, Fong-Yuan, additional, Tsai, Chih-Ping, additional, Chang, Wen-Hsun, additional, Hsu, Yen-Mei, additional, Lee, Na-Rong, additional, Chen, Chih-Yao, additional, Chang, Ting-Chen, additional, Chang, Wen-Chun, additional, Chen, Chii-Hou, additional, Chen, Ruey-Jian, additional, Chow, Song-Nan, additional, Lien, Yih-Ron, additional, Sheu, Bor-Ching, additional, Torng, Pao-Ling, additional, Yen, Men-Luh, additional, Lee, Wen-Ling, additional, Wang, Kuan-Chin, additional, Chang, Chih-Long, additional, Chen, Chih-Ping, additional, Chen, Jen-Ruei, additional, Chen, Tze-Chien, additional, Huang, Jian-Pei, additional, Huang, Ming-Chao, additional, Wang, Yeou-Lih, additional, Chang, Cheng-Chang, additional, Liu, Jah-Yao, additional, Su, Her-Young, additional, Wang, Yu-Chi, additional, Yu, Mu-Hsien, additional, Huang, Lee-Wen, additional, Seow, Kok-Min, additional, Lai, Tsung-Hsuan, additional, Lee, Fa-Kung, additional, Chen, Ching-Hui, additional, Huang, Ben-Shian, additional, Hsiao, Sheng-Mou, additional, Sun, Hsu-Dong, additional, Wu, Wen-Yih, additional, Teng, Sen-Wen, additional, Chen, Kuo-Hu, additional, Hung, Jeng-Hsiu, additional, Lai, Hung-Cheng, additional, Yuan, Chiou-Chung, additional, Hsieh, Ching-Hung, additional, Wang, Chin-Jung, additional, Chang, Shing-Jyh, additional, Hung, Man-Jung, additional, Hsu, Shih-Tien, additional, Ke, Yu-Min, additional, Lu, Chien-Hsing, additional, Sun, Lou, additional, Chang, Wei-Chun, additional, Hung, Yao-Ching, additional, Lin, Wu-Chou, additional, Wang, Po-Hui, additional, Chen, Tze-Ho, additional, Li, Yiu-Tai, additional, Wu, Meng-Hsing, additional, Huang, Kuo-Feng, additional, Fu, Hung-Chun, additional, Chen, San-Nung, additional, Chiang, An-Jen, additional, Li, Ju-Yueh, additional, Lin, Li-Te, additional, Tsai, Hsiao-Wen, additional, and Tsui, Kuan-Hao, additional

Published
2016
Full Text
View/download PDF

44. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma

Author

Sung, Pi-Lin, primary, Jan, Yi-Hua, additional, Lin, Shih-Chieh, additional, Huang, Chao-Cheng, additional, Lin, Hao, additional, Wen, Kuo-Chang, additional, Chao, Kuan-Chong, additional, Lai, Chiung-Ru, additional, Wang, Peng-Hui, additional, Chuang, Chi-Mu, additional, Wu, Hua-Hsi, additional, Twu, Nae-Fang, additional, Yen, Ming-Shyen, additional, Hsiao, Michael, additional, and Huang, Chi-Ying F., additional

Published
2015
Full Text
View/download PDF

45. Comparison of single-incision mini-slings (Ajust) and standard transobturator midurethral slings (Align) in the management of female stress urinary incontinence: A 1-year follow-up

Author

Chang, Chia-Pei, primary, Chang, Wen-Hsun, additional, Hsu, Yen-Mei, additional, Chen, Yi-Jen, additional, Wen, Kuo-Chang, additional, Chao, Kuan-Chong, additional, Yen, Ming-Shyen, additional, Horng, Huann-Cheng, additional, Wang, Peng-Hui, additional, Chuang, Chi-Mu, additional, Chang, Yen-Hou, additional, Wu, Hua-Hsi, additional, Lau, Hei-Yu, additional, Tseng, Jen-Yu, additional, Tsai, Hsiao-Wen, additional, Twu, Nae-Fong, additional, and Chao, Hsiang-Tai, additional

Published
2015
Full Text
View/download PDF

47. Second-Line Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian, Tubal and Peritoneal Cancer: A Propensity Score-Matching Study.

Author

Lu, Chien-Hsing, Chang, Yen-Hou, Lee, Wai-Hou, Chang, Yi, Peng, Chia-Wen, and Chuang, Chi-Mu

Subjects
CANCER chemotherapy, OVARIAN epithelial cancer, PROPENSITY score matching, INTRAVENOUS therapy, PERITONEAL cancer
Abstract

Background: The superiority of frontline intraperitoneal (IP) over intravenous (IV) chemotherapy is well established in the treatment of epithelial ovarian cancer. However, the role of IP chemotherapy in the second-line setting has rarely been investigated. Methods: Consecutive patients diagnosed with recurrent epithelial, tubal and peritoneal cancers between January 2000 and December 2012 were recruited using a propensity score-matching technique to adjust relevant risk factors. Results: In total, 310 patients were included in the final analysis (94 for platinum-refractory/resistant disease and 216 for platinum-sensitive disease). IP chemotherapy demonstrated significantly longer median progressionfree survival than IV chemotherapy (4.9 vs. 2.4 months, p < 0.001, for platinum-refractory/resistant disease, and 9.8 vs. 6.9 months, p < 0.001, for platinum-sensitive disease). Conclusions: Second-line IP chemotherapy confers longer progression- free survival than IV chemotherapy. Large-scale clinical trials should be conducted to validate the true efficacy. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

48. Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.

Author

Yen-Hou Chang, Wai-Hou Li, Yi Chang, Chia-Wen Peng, Ching-Hsuan Cheng, Wei-Pin Chang, Chi-Mu Chuang, Chang, Yen-Hou, Li, Wai-Hou, Chang, Yi, Peng, Chia-Wen, Cheng, Ching-Hsuan, Chang, Wei-Pin, and Chuang, Chi-Mu

Subjects
INTRAPERITONEAL injections, CANCER chemotherapy, PERITONEAL dialysis, CANCER patients, MORTALITY, PATIENTS, CARCINOGENESIS, CISPLATIN, COMPARATIVE studies, INJECTIONS, INTRAVENOUS therapy, RESEARCH methodology, MEDICAL cooperation, OVARIAN tumors, PROGNOSIS, RESEARCH, RISK assessment, TUMOR classification, PERITONEUM tumors, EVALUATION research
Abstract

Background: In the analysis of survival data for cancer patients, the problem of competing risks is often ignored. Competing risks have been recognized as a special case of time-to-event analysis. The conventional techniques for time-to-event analysis applied in the presence of competing risks often give biased or uninterpretable results.Methods: Using a prospectively collected administrative health care database in a single institution, we identified patients diagnosed with stage III or IV primary epithelial ovarian, tubal, and peritoneal cancers with minimal residual disease after primary cytoreductive surgery between 1995 and 2012. Here, we sought to evaluate whether intraperitoneal chemotherapy outperforms intravenous chemotherapy in the presence of competing risks. Unadjusted and multivariable subdistribution hazards models were applied to this database with two types of competing risks (cancer-specific mortality and other-cause mortality) coded to measure the relative effects of intraperitoneal chemotherapy.Results: A total of 1263 patients were recruited as the initial cohort. After propensity score matching, 381 patients in each arm entered into final competing risk analysis. Cumulative incidence estimates for cancer-specific mortality were statistically significantly lower (p = 0.017, Gray test) in patients receiving intraperitoneal chemotherapy (5-year estimates, 34.5%; 95% confidence interval [CI], 29.5-39.6%, and 10-year estimates, 60.7%; 95% CI, 52.2-68.0%) versus intravenous chemotherapy (5-year estimates, 41.3%; 95% CI, 36.2-46.3%, and 10-year estimates, 67.5%, 95% CI, 61.6-72.7%). In subdistribution hazards analysis, for cancer-specific mortality, intraperitoneal chemotherapy outperforms intravenous chemotherapy (Subdistribution hazard ratio, 0.82; 95% CI, 0.70-0.96) after correcting other covariates.Conclusions: In conclusion, results from this comparative effectiveness study provide supportive evidence for previous published randomized trials that intraperitoneal chemotherapy outperforms intravenous chemotherapy even eliminating the confounding of competing risks. We suggest that implementation of competing risk analysis should be highly considered for the investigation of cancer patients who have medium to long-term follow-up period. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

49. A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors.

Author

Wang, Shyh-Jen, Huang, Wen-Sheng, Chuang, Chi-Mu, Chang, Chih-Hsien, Lee, Te-Wei, Ting, Gann, Chen, Ming-Huang, Chang, Peter Mu-Hsin, Chao, Ta-Chung, Teng, Hao-Wei, Chao, Yee, Chen, Yuh-Min, Lin, Tzu-Ping, Chang, Ya-Jen, Chen, Su-Jung, Huang, Yuan-Ruei, and Lan, Keng-Li

Subjects
RADIATION dosimetry, LIPOSOMES, PHARMACOKINETICS, NUCLEAR energy, NUCLEAR research, TUMOR growth
Abstract

Background: Liposomes are drug nano-carriers that are capable of targeting therapeutics to tumor sites because of enhanced permeability retention (EPR). In several preclinical studies with various tumor-bearing mice models, 188Re-liposome that has been developed by the Institute of Nuclear Energy Research (INER) demonstrates favorable in vivo tumor targeting, biodistribution, pharmacokinetics, and dosimetry. It inhibits the growth of tumors, increased survival, demonstrates good synergistic combination, and was safe to use. This study conducts a phase 0 low-radioactivity clinical trial of nano-targeted radiotherapeutics 188Re-liposome to evaluate the effectiveness with which it targets tumors and the pharmacokinetics, biodistribution, dosimetry, and its safety in use. Twelve patients with metastatic cancers are studied in this trial. Serial whole-body scans and SPECT/CT are taken at 1, 4, 8, 24, 48, and 72 h after intravenous injection of 111 MBq of 188Re-liposome. The effectiveness with which tumors are targeted, the pharmacokinetics, biodistribution, dosimetry, and safety are evaluated using the VelocityAI and OLINDA/EXM software. Blood samples are collected at different time points for a pharmacokinetics study and a safety evaluation that involves monitoring changes in liver, renal, and hematological functions. Results: The T½z for 188Re-liposome in blood and plasma are 36.73 ± 14.00 h and 52.02 ± 45.21 h, respectively. The doses of radiation that are absorbed to vital organs such as the liver, spleen, lung, kidney, and bone marrow are 0.92 ± 0.35, 1.38 ± 1.81, 0.58 ± 0.28, 0.32 ± 0.09, and 0.06 ± 0.01 mGy/MBq, respectively, which is far less than the reference maximum tolerance dose after injection of 188Re-liposome. 188Re-liposome is absorbed by metastatic tumor lesions and the normal reticuloendothelial (RES) system. Certain patients exhibit a therapeutic response. Conclusion: This phase 0 exploratory IND study shows that nanocarrier 188Re-liposome achieves favorable tumor accumulation and tumor to normal organ uptake ratios for a subset of cancer patients. The clinical pharmacokinetic, biodistribution, and dosimetry results justify a further dose-escalating phase 1 clinical trial. Trial registration: Taiwan FDA MA1101G0 (Jan 31, 2012). [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

50. 188 Re-Liposome Can Induce Mitochondrial Autophagy and Reverse Drug Resistance for Ovarian Cancer: From Bench Evidence to Preliminary Clinical Proof-of-Concept.

Author

Chang CM, Lan KL, Huang WS, Lee YJ, Lee TW, Chang CH, and Chuang CM

Subjects
Animals, CA-125 Antigen blood, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Drug Resistance, Neoplasm drug effects, Female, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Microtubule-Associated Proteins metabolism, Mitochondria metabolism, Mitochondria pathology, Nanomedicine, Neoplastic Stem Cells cytology, Neoplastic Stem Cells drug effects, Neoplastic Stem Cells metabolism, Ovarian Neoplasms pathology, Ovarian Neoplasms radiotherapy, Radioisotopes chemistry, Radiopharmaceuticals chemistry, Radiopharmaceuticals therapeutic use, Rhenium chemistry, Transplantation, Heterologous, Autophagy drug effects, Liposomes chemistry, Mitochondria drug effects, Radiopharmaceuticals toxicity
Abstract

Despite standard treatment, about 70% of ovarian cancer will recur. Cancer stem cells (CSCs) have been implicated in the drug-resistance mechanism. Several drug resistance mechanisms have been proposed, and among these, autophagy plays a crucial role for the maintenance and tumorigenicity of CSCs. Compared to their differentiated counterparts, CSCs have been demonstrated to display a significantly higher level of autophagy flux. Moreover, mitophagy, a specific type of autophagy that selectively degrades excessive or damaged mitochondria, is shown to contribute to cancer progression and recurrence in several types of tumors. Nanomedicine has been shown to tackle the CSCs problem by overcoming drug resistance. In this work, we developed a nanomedicine, 188 Re-liposome, which was demonstrated to target autophagy and mitophagy in the tumor microenvironment. Of note, the inhibition of autophagy and mitophagy could lead to significant tumor inhibition in two xenograft animal models. Lastly, we presented two cases of recurrent ovarian cancer, both in drug resistance status that received a level I dose from a phase I clinical trial. Both cases developing drug resistance showed drug sensitivity to 188 Re-liposome. These results suggest that inhibition of autophagy and mitophagy by a nanomedicine may be a novel strategy to overcome drug resistance in ovarian cancer.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results